Medline
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Below its 200-day average or in the bottom third on momentum — the strategy is out of it.
- Signal has read SELL for 3 days.
- Recent price momentum is +13.7% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 4.3% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-22 02:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation C
How expensive the stock is versus earnings, sales and its own 5-year history.
| P/E (TTM) | 57.5x | Better than 8% |
| Forward P/E | 22.1x | Better than 30% |
| Price / Sales | 1.1x | Better than 76% |
| P/E vs own 5-yr range | 69th pctl | Better than 39% |
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability B-
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 26.4% | Better than 27% |
| Operating margin | 7.8% | Better than 44% |
| Net margin | 4.1% | Better than 40% |
| Return on equity | 21.3% | Better than 80% |
| Return on invested capital | 9.5% | Better than 66% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | 8.1% | Better than 88% |
| 6-month return | 0.1% | Better than 56% |
| Distance below 52-week high | 27.2% | Better than 47% |
Financial Health B-
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 4.3x | Better than 82% |
| Debt to assets | 32.8% | Better than 37% |
| Interest coverage | 2.5x | Better than 41% |
| Free cash flow / net income | 111.9% | Better than 46% |
Analyst View B+
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 77% |
| Upside to average target | 28.6% | Better than 47% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 37.84
- Open
- 37.65
- Day range
- 36.94 - 38.37
- Avg price
- 37.32
- Volume
- 9.33M
- Turnover
- 348.25M
- Turnover ratei
- 2.44%
- Volume ratioi
- 0.61
- Amplitudei
- 3.78%
- 52-week rangei
- 31.37 - 50.88
Valuation
- P/Ei
- 25.96
- P/E (TTM)i
- 57.52
- P/Bi
- 2.76
- EPSi
- 1.43
- Book value / shi
- 13.43
- Net profit
- 1.25B
- Net assets
- 11.80B
Share structure
- Market cap
- 32.55B
- Float capi
- 14.15B
- Shares out
- 878.66M
- Float sharesi
- 382.04M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2025-12-17
27.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-37.07M net over the window
Short interest
- Shares short
- 37.84M
- % of floati
- 4.31%
- Days to coveri
- 3.79
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Medline (MDLN)?
Medline last traded at 37.04. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Medline's market cap?
About 32.55B.
What is the P/E ratio of Medline?
The trailing twelve-month P/E is 57.52, above its own 5-year average of 40.81 — toward the top of its historical range (69.01% percentile). See the Valuation tab for the full history.
Does Medline pay a dividend?
Medline does not currently pay a regular dividend.
Is Medline a buy according to analysts?
The consensus of 17 analysts is a Buy rating, with an average 12-month price target of 47.64, which implies 28.6% upside from the current price. This is not investment advice.
What is Medline's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Medline a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.
Quote time 2026-11-20 19:30:05 · For reference only, not investment advice and not tailored to your situation.
Medline discussion 0 comments